Daewoong Pharmaceutical announced on July 25th that its premium botulinum toxin, ‘Nabota,’ has secured an export contract to Kuwait, further strengthening its position in the Middle Eastern market.
This deal marks Daewoong’s fifth entry into the Middle East and the fourth within the Gulf Cooperation Council (GCC) countries. After establishing a presence in the UAE, Saudi Arabia, and Qatar, the company is now expanding into Kuwait, reinforcing its influence in the Gulf region’s high-end cosmetic and plastic surgery markets.
Kuwait, with a per capita GDP of around $32,000 and a well-developed healthcare system, presents a promising growth opportunity for the healthcare industry. The country’s strong ties with neighboring Gulf nations make it a strategic hub for future expansion across the Middle East. Daewoong plans to use Kuwait as a gateway to supply Nabota throughout the entire GCC market.
Currently, Daewoong is the Korean botulinum toxin company with the broadest Middle Eastern reach, leveraging not only product exports but also comprehensive strategies such as medical staff training, academic collaborations, and research initiatives.
The company continues to innovate with proprietary techniques like combination procedures and the ‘Naboreift’ program, hosting conferences, webinars, and training sessions to demonstrate the quality and safety of Nabota. Collaborative research with local medical professionals further substantiates Nabota’s efficacy, fostering a ‘WIN-WIN-WIN’ model that benefits companies, practitioners, and patients.
Junsu Yoon, Head of Nabota Business at Daewoong, stated, “Expanding into Kuwait signifies Nabota’s growing recognition as a leading brand in the Middle East’s premium neurotoxin market. With robust clinical data and differentiated procedures, we aim to rapidly extend our influence across the entire Middle East region.”
